首页> 美国卫生研究院文献>Molecular Medicine Reports >Quercetin-3-O-β-D-glucoside decreases the bioavailability of cyclosporin A through regulation of drug metabolizing enzymes transporters and nuclear receptors in rats
【2h】

Quercetin-3-O-β-D-glucoside decreases the bioavailability of cyclosporin A through regulation of drug metabolizing enzymes transporters and nuclear receptors in rats

机译:槲皮素-3-O-β-D-葡萄糖苷通过调节大鼠体内的药物代谢酶转运蛋白和核受体来降低环孢菌素A的生物利用度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Quercetin is a flavonoid compound that is widely present in food and drink. Quercetin-3-O-β-D-glucoside (Q3GA) is a major metabolite of quercetin. The aim of the present study was to investigate the effect of Q3GA on the pharmacokinetics of orally and intravenously administered cyclosporin A (CsA) in rats, and to assess the effect of Q3GA on drug-metabolizing enzymes (DMEs), drug transporters (DTs) and nuclear receptors (NRs). The pharmacokinetic parameters of CsA were measured following oral (10 mg/kg) and intravenous (2.5 mg/kg) administration of CsA in the presence or absence of Q3GA. The mRNA and protein expression levels of DMEs, DTs and NRs in the liver and small intestine were detected by quantitative polymerase chain reaction and western blot analysis. The results indicated that the intravenous administration of Q3GA (2.5, 5 or 10 mg/kg) for 7 consecutive days reduced the bioavailability of oral CsA. By contrast, the pharmacokinetics of the intravenous administration of CsA were not affected by Q3GA. However, the mRNA and protein expression levels of DMEs and DTs were inhibited by Q3GA. The activation of DMEs and DTs by NRs, and the interplay between DMEs and DTs, may explain these results. The present study identified a novel flavonoid-drug interaction, which may have implications for patients taking CsA and quercetin supplements or on a quercetin-containing diet.
机译:槲皮素是一种类黄酮化合物,广泛存在于食品和饮料中。槲皮素-3-O-β-D-葡萄糖苷(Q3GA)是槲皮素的主要代谢产物。本研究的目的是研究Q3GA对大鼠口服和静脉内给予环孢菌素A(CsA)的药代动力学的影响,并评估Q3GA对药物代谢酶(DME),药物转运蛋白(DTs)的影响和核受体(NRs)。在存在或不存在Q3GA的情况下口服(10 mg / kg)和静脉内(2.5 mg / kg)施用CsA后,测量CsA的药代动力学参数。通过定量聚合酶链反应和蛋白质印迹分析检测肝脏和小肠中DMEs,DTs和NRs的mRNA和蛋白表达水平。结果表明,连续7天静脉内施用Q3GA(2.5、5或10 mg / kg)会降低口服CsA的生物利用度。相比之下,C3A静脉内给药的药代动力学不受Q3GA的影响。然而,Q3GA抑制DMEs和DTs的mRNA和蛋白表达水平。 NR对DME和DT的激活以及DME和DT之间的相互作用可能解释了这些结果。本研究确定了一种新型的类黄酮-药物相互作用,这可能对服用CsA和槲皮素补充剂或含有槲皮素的饮食的患者产生影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号